YMAB Reconciled Depreciation from 2010 to 2025

YMAB Stock  USD 4.67  0.06  1.27%   
Y MAbs' Reconciled Depreciation is increasing over the years with slightly volatile fluctuation. Reconciled Depreciation is expected to dwindle to about 488.3 K. From 2010 to 2025 Y MAbs Reconciled Depreciation quarterly data regression line had arithmetic mean of  252,454 and r-squared of  0.67. View All Fundamentals
 
Reconciled Depreciation  
First Reported
2018-06-30
Previous Quarter
121 K
Current Value
102 K
Quarterly Volatility
78 K
 
Covid
Check Y MAbs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Y MAbs' main balance sheet or income statement drivers, such as Interest Expense of 821.4 K, Selling General Administrative of 36.2 M or Total Revenue of 92.1 M, as well as many indicators such as Price To Sales Ratio of 3.76, Dividend Yield of 0.0 or PTB Ratio of 3.58. YMAB financial statements analysis is a perfect complement when working with Y MAbs Valuation or Volatility modules.
  
Check out the analysis of Y MAbs Correlation against competitors.

Latest Y MAbs' Reconciled Depreciation Growth Pattern

Below is the plot of the Reconciled Depreciation of Y mAbs Therapeutics over the last few years. It is Y MAbs' Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Y MAbs' overall financial position and show how it may be relating to other accounts over time.
Reconciled Depreciation10 Years Trend
Slightly volatile
   Reconciled Depreciation   
       Timeline  

YMAB Reconciled Depreciation Regression Statistics

Arithmetic Mean252,454
Geometric Mean0.00
Coefficient Of Variation131.45
Mean Deviation291,192
Median29,000
Standard Deviation331,861
Sample Variance110.1B
Range839K
R-Value0.82
Mean Square Error39.5B
R-Squared0.67
Significance0.0001
Slope56,846
Total Sum of Squares1.7T

YMAB Reconciled Depreciation History

2025488.3 K
2024535 K
2023804 K
2022839 K
2021782 K
2020396 K
2019166 K

About Y MAbs Financial Statements

Y MAbs stakeholders use historical fundamental indicators, such as Y MAbs' Reconciled Depreciation, to determine how well the company is positioned to perform in the future. Although Y MAbs investors may analyze each financial statement separately, they are all interrelated. For example, changes in Y MAbs' assets and liabilities are reflected in the revenues and expenses on Y MAbs' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Y mAbs Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Reconciled Depreciation535 K488.3 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Y mAbs Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Y MAbs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Y Mabs Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Y Mabs Therapeutics Stock:
Check out the analysis of Y MAbs Correlation against competitors.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.67)
Revenue Per Share
1.978
Quarterly Revenue Growth
0.134
Return On Assets
(0.13)
Return On Equity
(0.31)
The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.